 VANCOUVER, British Columbia and SEATTLE, April 01, 2021 GLOBE NEWSWIRE -- Chinook Therapeutics, Inc. Nasdaq: KDNY, a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Companys Board of Directors approved new employment inducement grants of stock options to purchase a total of 83,599 shares of common stock with a grant date of March 31, 2021 the Inducement Grants for two new employees. 